The ITSN2 Knockout NCI-H1975 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma cell line. This pooled knockout format preserves genetic heterogeneity and is designed to achieve targeted disruption of the ITSN2 gene, generating a loss-of-function model for functional studies. The polyclonal approach avoids single-cell cloning artifacts and may more closely recapitulate the varied responses observed in tumor cell populations, making it suitable for robust and reproducible experimentation in cancer signaling research.
The NCI-H1975 parental line originates from a non-small cell lung cancer patient and serves as a well-characterized model of lung adenocarcinoma. These epithelial cells harbor oncogenic mutations typical of advanced lung cancer and are extensively utilized to investigate tumor biology, signal transduction pathways, and therapeutic responses. The adherent growth properties and consistent culture requirements of NCI-H1975 cells facilitate their use in a broad range of in vitro assays and make them a reliable host for genetic perturbation studies.
Intersectin-2 (ITSN2) is a multidomain scaffold protein that plays a critical role in coupling endocytic trafficking to actin cytoskeleton dynamics. Upon stimulation by epidermal growth factor (EGF), ITSN2 is recruited to activated epidermal growth factor receptor (EGFR) and orchestrates the assembly of the endocytic machinery through direct interactions with Dynamin and the phosphoinositide phosphatase Synaptojanin. Simultaneously, ITSN2 engages the actin nucleation-promoting factor N-WASP and the small GTPase CDC42 to drive local actin polymerization, thereby linking vesicle internalization to cytoskeletal remodeling. Through this dual function, ITSN2 modulates key downstream signaling cascades, including the mitogen-activated protein kinase (MAPK) and AKT pathways, which regulate cell proliferation, survival, and migration.
In the context of NCI-H1975 lung adenocarcinoma cells, where EGFR signaling is frequently hyperactive and contributes to malignant progression, targeted disruption of ITSN2 provides a means to dissect the contribution of endocytosis-dependent regulation to oncogenic output. Impairment of ITSN2-mediated EGFR internalization is anticipated to alter the strength and duration of MAPK and AKT pathway activities, potentially affecting cellular behaviors such as proliferation and motility. This knockout model thus enables investigation of how scaffold proteins interface with receptor tyrosine kinase networks to shape cancer cell phenotypes, offering a platform to explore the molecular underpinnings of non-small cell lung cancer.
The ITSN2 knockout polyclonal population is well-suited for a variety of experimental applications, including detailed analysis of EGFR trafficking using endocytosis assays, quantification of signaling changes via Western blot detection of phosphorylated MAPK and AKT, and assessment of functional outcomes through cell proliferation and transwell migration/invasion assays. Immunofluorescence microscopy allows visualization of actin cytoskeleton reorganization and the subcellular distribution of ITSN2-interacting partners. This model is particularly valuable for studying mechanisms of resistance to EGFR-targeted therapies and for conducting drug screens aimed at modulating endocytosis-dependent signaling pathways in lung adenocarcinoma. For further information, please contact Ascent Research.
